Insulin Dosing Function System Using Reinforcement Learning
Summary
The USPTO has published a patent application (US20260083909A1) detailing a system and method for calculating an insulin dosing function using reinforcement learning. The application describes a process that utilizes self-attention and a State-Action-Reward-Next State sequence to optimize insulin dosage decisions in automated medical systems.
What changed
This document is a patent application (US20260083909A1) filed with the USPTO, describing a novel system for calculating insulin dosing functions. The core innovation lies in the application of reinforcement learning with self-attention mechanisms to an automated medical system. The system uses a State-Action-Reward-Next State (SARS) sequence, where the state includes continuous glucose monitoring readings, insulin doses, meal information, and activity levels. The agent learns to determine optimal insulin doses by receiving rewards based on resulting glucose levels and updating its neural network weights through iterative learning.
This patent application does not impose immediate regulatory obligations. However, it signals potential future technological advancements in diabetes management and automated insulin delivery systems. Companies involved in developing medical devices, particularly those related to diabetes care and AI-driven health solutions, should be aware of this patent filing as it may impact intellectual property landscapes and future product development strategies in this sector.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
SYSTEM AND METHOD FOR CALCULATING AN INSULIN DOSING FUNCTION
Application US20260083909A1 Kind: A1 Mar 26, 2026
Inventors
Anas El Fathi, Marc D. Breton, Elliott C. Pryor, Ali Tavasoli, Heman Shakeri
Abstract
A reinforcement learning process with self attention is used for insulin dosing decisions in an automated medical system. The State-Action-Reward-Next State (SARS) sequence is used. The state represents the current condition, including recent continuous glucose monitoring readings, insulin doses, meal information, and potentially other relevant factors like time of day or physical activity levels. Based on this state, the agent takes an action by deciding on an insulin dose. It then receives a reward, a numerical value quantifying the quality of the action, based on resulting glucose levels and their proximity to the target range. This leads to a new state, and the process repeats. Through this iterative process, the algorithm updates the neural network weights, allowing the agent to learn which actions lead to better outcomes in different states.
CPC Classifications
A61M 5/1723 G06N 3/092 G16H 20/17 A61M 2230/201
Filing Date
2025-09-22
Application No.
19335674
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Medical Devices (A61M)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Medical Devices (A61M) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.